References
- EMA: Medicines | European Medicines Agency (europa.eu). [Internet]. Amsterdam. [cited 2023 Nov 15]. Available from: https://www. ema.europa.eu/en/medicines searched <“monoclonal” between 2013 November 14 and 2023 November 14 excluded “biosimilars” + “withdrawn products”>
- ICH: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Harmonised guideline. Organisation of the common technical document for the registration of pharmaceuticals for human use (M4). Current Step 4 Version. 2016 Jun 15 [cited 2023 Nov 15].
- CHMP: Committee for Medicinal Products for Human Use (CHMP) Guideline on non-clinical and clinical development of similar biological medicinal products containing low molecular-weight-heparins [internet]. 2016 Nov 10 [cited 2023 Nov 15]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-non-clinical-and-clinical-development-similar-biological-medicinal-products-containing-low-molecular-weight-heparins-revision-1_en.pdf
- FDA: “deemed to be a license” provision of the BPCI Act. 2020 Apr 4 [cited 2023 Nov 15]. Available from: https://www.fda.gov/drugs/guidance-compliance-regulatory-information/deemed-be-license-provision-bpci-act#:~:text=The%20Biologics%20Price%20Competition%20and,biologics%20license%20application%20(BLA)%20under
- CHMP: Assessment report: Remsima® (INN: infliximab). Procedure No. EMEA/H/C/002576/000. 2013 June 27 [cited 2024 Feb 12]. Available at: https://www.ema.europa.eu/en/documents/assessment-report/remsima-epar-public-assessment-report_en.pdf
- EMA. Amsterdam: Medicines | European Medicines Agency (europa.eu). [cited 2023 Nov 15]. Available from: https://www.ema.europa.eu/en/homepage <searched “biosimilars” + “EPAR” + “withdrawn” + “refused”>
- CHMP: Assessment report: Lutholaz® (INN: pegfilgrastim). Procedure No. EMEA/H/C/005587/0000 Lutholaz: Withdrawal of the marketing authorisation application. EMA/CHMP/343552/2023EMA/CHMP/343552/2023. Amsterdam. 2023 Apr 26 [cited 2023 Nov 15]. Available from: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lutholaz_en.pdf
- CHMP: Withdrawal of application for the marketing authorisation of Hervelous® (INN: trastuzumab). Rev.1 EMA/807465/2022 EMEA/H/C/005066. Amsterdam. 2022 Oct 17 [cited 2023 Nov 15]. Available from: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-hervelous_en.pdf
- CHMP: Questions and answers withdrawal of the marketing authorisation application for Epostim® (INN: epoetin alfa). EMA/287731/2011 EMEA/H/C/002265. 2011 Apr 14 [cited 2023 Apr 14]. Available from: https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-marketing-authorisation-application-epostim-epoetin-alfa_en.pdf
- CHMP: Withdrawal of application for the marketing authorisation of Teriparatide Cinnagen (INN: teriparatide). EMA/509904/2021 EMEA/H/C/005543. 2021 Sep 17 [cited 2023 Nov 15]. Available from: https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-teriparatide-cinnagen-teriparatide_en.pdf
- CHMP: Assessment report: Solumarv® (INN: insulin human) procedure No. EMEA/H/C/003858/0000. EMA/596513/2015. 2015 Nov 19 [cited 2023 Nov 15]. Available from: https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-solumarv-insulin-human_en.pdf
- CHMP: Refusal assessment report for Alpheon® (INN: recombinant human interferon-alfa-2a). Procedure No. EMEA/H/C/000585. 2007 Oct 22 [cited 2023 Nov 15]. Available from: https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-alpheon_en.pdf
- Schiestl M, Ranganna G, Watson K, et al. The path towards a tailored clinical biosimilar development. BioDrugs. 2020 Jun;34(3):297–306. doi: 10.1007/s40259-020-00422-1
- EMA: EPAR Ontruzant® (INN: trastuzumab). EMA/CHMP/9855/2018. 2017 Sep 14 [cited 2023 Nov 15]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/ontruzant-epar-public-assessment-report_en-0.pdf
- EMA: EPAR Kanjinti (INN: trastuzumab). EMA/CHMP/261937/2018. 2018 Mar 22 [cited 2023 Nov 15]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/kanjinti-epar-public-assessment-report_en.pdf.
- FDA: Kanjinti® (USAN: trastuzumab anns) review application no 761073. 2019 Jul 18 [cited 2023 Nov 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761073Orig1s000TOC.cfm
- FDA: Ontruzant (USAN: trastuzumab dttb) review application no 761100. 2019 Mar 5 [cited 2023 Nov]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761100Orig1s000TOC.cfm
- Kim S, Song J, Park S, et al. Drifts in ADCC-related quality attributes of Herceptin®: impact on development of a trastuzumab biosimilar. MAbs. 2017 May;9(4):704–714. doi: 10.1080/19420862.2017.1305530
- Kirsch-Stefan N, Guillen E, Ekman N, et al. Do the outcomes of clinical efficacy trials matter in regulatory decision-making for biosimilars? BioDrugs. 2023;37(6):855–871. doi: 10.1007/s40259-023-00631-4
- Liu H, Ponniah G, Zhang HM, et al. In vitro and in vivo modifications of recombinant and human IgG antibodies. MAbs. 2014;6(5):1145–1154.
- Schuster J, Koulov A, Mahler HC, et al. In vivo stability of therapeutic proteins. Pharm Res. 2020 3;37(2):23. doi: 10.1007/s11095-019-2689-1
- Boune S, Hu P, Epstein AL, et al. Principles of N-linked glycosylation variations of IgG-based therapeutics: pharmacokinetic and functional considerations. Antibodies (Basel). 2020 Jun 10;9(2): 22. doi: 10.3390/antib9020022
- Cambay F, Raymond C, Brochu D, et al. Impact of IgG1 N-glycosylation on their interaction with Fc gamma receptors. Curr Res Immunol. 2020 Jun 27;1:23–37. doi: 10.1016/j.crimmu.2020.06.001
- Wada R, Matsui M, Kawasaki N. Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms. MAbs. 2018;11(2):350–372. doi: 10.1080/19420862.2018.1551044
- Yu M, Brown D, Reed C, et al. Production, characterization and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans. MAbs. 2012;4(4):475–487. doi: 10.4161/mabs.20737
- Scheiblhofer S, Laimer J, Machado Y, et al. Influence of protein fold stability on immunogenicity and its implications for vaccine design. Expert Rev Vaccines. 2017 May;16(5):479–489. doi: 10.1080/14760584.2017.1306441
- Lundahl MLE, Fogli S, Colavita PE, et al. Aggregation of protein therapeutics enhances their immunogenicity causes and mitigation strategies. RSC Chem Biol. 2021 May 4;2(4):1004–1020. doi: 10.1039/d1cb00067e
- Raut S, Di Giambattista M, Bevan SA, et al. Modification of factor VIII in therapeutic concentrates after virus inactivation by solvent-detergent and pasteurisation. Thromb Haemost. 1998;80(4):624–631.
- Swanson MD, Rios S, Mittal S, et al. Immunogenicity risk assessment of spontaneously occurring therapeutic monoclonal antibody aggregates. Front Immunol. 2022 Jul 27;13:915412. doi: 10.3389/fimmu.2022.915412
- Carpenter JF, Randolph TW, Jiskoot W, et al. Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J Pharm Sci. 2009 Apr;98(4):1201–1205. doi: 10.1002/jps.21530
- Jaffar-Aghaei M, Khanipour F, Maghsoudi A, et al. QbD-guided pharmaceutical development of pembrolizumab biosimilar candidate PSG-024 propelled to industry meeting primary requirements of comparability to Keytruda®. Eur J Pharm Sci. 2022 Jun 1;173:106171. doi: 10.1016/j.ejps.2022.106171
- Bumbaca D, Boswell CA, Fielder PJ, et al. Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics. AAPS J. 2012;14(3):554–558. doi: 10.1208/s12248-012-9369-y
- Wang W, Vlasak J, Li Y, et al. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies. Mol Immunol. 2011 Mar;48(6–7):860–866.
- Suzuki T, Ishii-Watabe A, Tada M, et al. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. The Journal of Immunology. 2010;184(4):1968–1976.
- CHMP: Assessment report Zarzio® (INN: filgrastim). Procedure No. EMEA/H/C/000917. 2009 Feb 16 [cited 2023 Nov 15]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/zarzio-epar-public-assessment-report_en.pdf
- FDA: Zarxio® review, FDA application no 125553. [cited 2023 Nov 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125553Orig1s000TOC.cfm
- CHMP: Assessment report Udencya® (INN: pegfilgrastim). Procedure No. EMEA/H/C/004413/0000. 2018 Jul 26 [cited 2023 Jul 26]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/udenyca-epar-public-assessment-report_en.pdf
- FDA: Udenyca® review, FDA application no 761039. 2019 Nov [cited 2023 Nov 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761039Orig1s000TOC.cfm
- CHMP: Assessment report Hyrimoz® International non-proprietary name: adalimumab Procedure No. EMEA/H/C/004320/0000. 2018 May 31 [cited Nov 2019]. https://www.ema.europa.eu/en/documents/assessment-report/hyrimoz-epar-public-assessment-report_en.pdf
- CHMP: Assessment report Cyltezo® (INN: adalimumab). Procedure No. EMEA/H/C/004319/0000. Procedure No. EMEA/H/C/004413/0000. 2014 Sep 17 [cited 2023 Sep 17]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/cyltezo-epar-public-assessment-report_en.pdf
- CHMP: Assessment report Ziextenzo® (INN: pegfilgrastim). Procedure No. EMEA/H/C/004802/000. 2018 Sep 20 [cited 2023 Sep 20]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/ziextenzo-epar-public-assessment-report_en.pdf
- CHMP: Assessment report Erelzi® (INN: etanercept). Procedure No. EMEA/H/C/004192/0000. 2017 Apr 21 [cited 2023 Nov 15]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/erelzi-epar-public-assessment-report_en.pdf
- VonRichter O, Lemke L, Haliduola H, et al. Differences in immunogenicity associated with non-product related variability: insights from two pharmacokinetic studies using GP2017, an adalimumab biosimilar. Exp Opin Biol Ther. 2019;19(10):1057–1064.
- CHMP: Assessment report Amgevita (INN: adalimumab). Procedure No. EMEA/H/C/004212/0000. 2017 Jan 15 [cited 2023 Nov 15]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/amgevita-epar-public-assessment-report_en.pdf
- CHMP: Committee for Medicinal Products for Human Use (CHMP) guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues [Internet]. London. 2014 Dec 18. EMA/CHMP/BWP/42832/2005 rev 1. [cited 2023 Nov 15]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-non-clinical-and-clinical-issues-revision-1_en.pdf
- Kuriakose A, Chirmule N, Nair P. Immunogenicity of biotherapeutics: causes and association with posttranslational modifications. J Immunol Res. 2016;2016:1–18. doi: 10.1155/2016/1298473
- Lundahl MLE, Fogli S, Colavita PE, et al. Aggregation of protein therapeutics enhances their immunogenicity causes and mitigation strategies. RSC Chem Biol. 2021 May 4;2(4):1004–1020. doi: 10.1039/d1cb00067e
- Thorlaksen C, Schultz HS, Gammelgaard SK, et al. In vitro and in vivo immunogenicity assessment of protein aggregate characteristics. Int J Pharm. 2023 Jan 25;631:122490. Epub 2022 Dec 13. PMID: 36521637. DOI: 10.1039/D1CB00067E (Review Article) RSC Chem. Biol. 2021;2:1004–1020. doi: 10.1016/j.ijpharm.2022.122490
- McKoy JM, Stonecash RE, Cournoyer D, et al. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion. 2008 Aug;48(8):1754–1762. doi: 10.1111/j.1537-2995.2008.01749.x
- Schellekens H, Jiskoot W. Erythropoietin-associated PRCA: still an unsolved mystery. J Immunotoxicol. 2006;3(3):123–130. doi: 10.1080/15476910600845567
- Jelkmann W. Biosimilar epoetins and other “follow-on” biologics: update on the European experiences. American J Hematol. 2010;85(10):771–780. doi: 10.1002/ajh.21805
- Vandivort TC, Horton DB, Johnson SB. Regulatory and strategic considerations for addressing immunogenicity and related responses in biopharmaceutical development programs. J Clin Transl Sci. 2020 Jun 15;4(6):547–555. doi: 10.1017/cts.2020.493
- Parikh CR, Ponnampalam JK, Seligmann G, et al. Impact of immunogenicity on clinical efficacy and toxicity profile of biologic agents used for treatment of inflammatory arthritis in children compared to adults. Ther Adv Musculoskelet Dis. 2021;13:13. doi: 10.1177/1759720X211002685
- EMA: Omnitrope® EPAR. 2006 Apr 24 [cited 2023 Nov 15] Available from: https://www.ema.europa.eu/en/documents/procedural-steps/omnitrope-epar-procedural-steps-taken-authorisation_en.pdf
- FDA: Immunogenicity testing of therapeutic protein products— developing and validating assays for anti-drug antibody detection guidance for industry. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). 2019 Jan [cited 2023 Nov 15]. Available from: https://www.fda.gov/media/119788/download
- Song S, Yang L, Trepicchio WL, et al. Understanding the supersensitive anti-drug antibody assay: unexpected high anti-drug antibody incidence and its clinical relevance. J Immunol Res. 2016;2016:1–8. doi: 10.1155/2016/3072586
- Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet. 1999 Dec 4;354(9194):1932–1939. doi: 10.1016/s0140-6736(99)05246-0
- Chatzidionysiou K, Lie E, Nasonov E, et al. Rheumatic diseases Portuguese register. Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. Arthritis Res Ther. 2016 Feb 16;18:50. doi: 10.1186/s13075-016-0951-z
- Turner DC, Kondic AG, Anderson KM, et al. Pembrolizumab exposure–response assessments challenged by association of cancer cachexia and catabolic clearance. Clin Cancer Res. 2018;24(23):5841–5849. doi: 10.1158/1078-0432.CCR-18-0415
- Chatterjee M, Turner DC, Felip E, et al. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. Ann Oncol. 2016 Jul;27(7):1291–1298. doi: 10.1093/annonc/mdw174
- Elahee M, Sattui SE. Navigating use of rituximab during the COVID-19 pandemic. Lancet Rheumatol. 2023 Feb;5(2):e63–e64. doi: 10.1016/S2665-9913(23)00005-X
- ICH: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Harmonised guideline. Population exposure: the extent of population exposure to assess clinical safety (E1). 1994 Oct 27 [cited 2023 Oct 27]. Available from: https://database.ich.org/sites/default/files/E1_Guideline.pdf
- MHRA: Guidance on the licensing of biosimilar products. 2022 Nov 7 [cited 2023 Nov 7]. Available from: https://www.gov.uk/government/publications/guidance-on-the-licensing-of-biosimilar-products/guidance-on-the-licensing-of-biosimilar-products
- Bielsky MC, Cook A, Wallington A, et al. Streamlined approval of biosimilars: moving on from the confirmatory efficacy trial. Drug Discov Today. 2020 Sep 9;S1359-6446(20):30343–3. doi: 10.1016/j.drudis.2020.09.006
- IPRP Biosimilars Working Group workshop: “Increasing the efficiency of biosimilar development programs-re-evaluating the need for comparative clinical efficacy studies (CES)” IPRP Biosimilars Working Group (BWG) session 1: Setting the stage—how have we been using comparative clinical efficacy studies (CES) in biosimilar development programs, and what have we learned? 2023 Sep 12 [cited 2023 Nov 15]. Available from: https://www.fda.gov./media/172197/download
- Ricci MS. Comparative efficacy studies: biosimilar approvals in the United States. Presented at IPRP Biosimilars working group workshop: “increasing the efficiency of biosimilar development programs-re-evaluating the need for comparative clinical efficacy studies (CES)” IPRP biosimilars working group (BWG) session 1: setting the stage—how have we been using comparative clinical efficacy studies (CES) in biosimilar development programs, and what have we learned? 2023 Sep 12 [cited 2023 Nov 15]. Available from: http://www.fda.gov/media/172197/download
- CHMP: Committee for Medicinal Products for Human Use (CHMP). Concept paper for the development of a reflection paper on a tailored clinical approach in biosimilar development. EMA/CHMP/BMWP/35061/2024. 2023 Nov 24 [cited 2024 November 15]. Available from: https://www.ema.europa.eu/en/documents/other/concept-paper-development-reflection-paper-tailored-clinical-approach-biosimilar-development_en.pdf